Olmesartan Medoxomil and Rosuvastatin Tablets 20/5 mg
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Hanpoong Pharmaceutical Co., Ltd.
MFDS item code 202003981 · Approved 2020.05.28
This product's status changed to Expired on 2025.05.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension, improvement of dyslipidemia, suppression of atherosclerosis progression and cardiovascular risk
This medication is used for patients who need to take Olmesartan Medoxomil and Rosuvastatin simultaneously. Olmesartan Medoxomil helps in treating essential hypertension. Rosuvastatin is used in cases of primary hypercholesterolemia and mixed dyslipidemia that are not controlled by diet and exercise, and it is also used as an adjunct treatment for homozygous familial hypercholesterolemia. Additionally, it helps as an adjunct for patients with dysbetalipoproteinemia and lowers total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis. In patients with elevated high-sensitivity C-reactive protein levels and cardiovascular disease risk factors, it reduces the risk of stroke, myocardial infarction, and arterial revascularization, thus improving cardiovascular health. Therefore, this medication is used to manage both hypertension and hyperlipidemia simultaneously to reduce the risk of cardiovascular diseases.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is necessary when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Special caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may be switched to this medicine (a fixed-dose combination with the same amount of each active ingredient) for convenience.
Safety and efficacy have not been established in children under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients who are allergic to this medication or its components, women who are pregnant or may become pregnant, women who are breastfeeding, and patients with severe renal or liver dysfunction should not take this medication. When initiating treatment in patients with low blood pressure or low sodium levels, hypotensive symptoms may occur, so caution is required, and if such symptoms arise, medical personnel should be notified immediately. Patients with impaired renal function or kidney transplant recipients should have their renal function and electrolyte levels monitored regularly through blood tests. This medication may cause hyperkalemia (increased serum potassium levels), so caution is needed when taken with potassium supplements or potassium-sparing diuretics. Elderly patients or Asians may experience increased drug exposure, necessitating dose adjustments. If symptoms such as myalgia, muscle weakness, myopathy, or rhabdomyolysis occur, medical personnel should be informed immediately, and the medication should be discontinued. Liver function abnormalities may occur, so routine liver function tests before and during treatment are recommended. This medication may interact with other drugs, so it is essential to inform medical personnel of any other medications being taken. One should be cautious about dizziness or drowsiness when driving or operating hazardous machinery. Patients who are pregnant or breastfeeding should not take this medication, and women who may become pregnant should use appropriate contraception. Safety and efficacy in children and adolescents under 18 years of age have not been established. In case of overdose, symptoms such as hypotension or palpitations may occur, and medical assistance should be sought immediately. This medication should be kept out of reach of children, and transferring it to different containers is not recommended as it may affect the quality.
Increase in ALT, increase in AST, increase in blood creatinine, decrease in creatinine clearance, headache, dizziness, sensory impairment, neuromuscular disease, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional dizziness), palpitations, increased blood pressure, low back pain, increased blood creatinine, diarrhea, pruritus, cough, epistaxis, upper respiratory tract infection, asthma, hypersensitivity reactions including angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, oculobulbar myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained at room temperature between 1°C and 30°C. Storing it this way helps preserve the effectiveness and safety of the medication.
White or light yellow round film-coated tablets
30 tablets/box [30 tablets (10 tablets/Alu-Alu) x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Hanpoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.